Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led studySophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic DiseaseMatthew R Smith, Shibu Thomas, Michael Gormley, et al.
Frontiers in Immunology|December 5, 2024
Immunome profiling in prostate cancer: a guide for cliniciansLuis San-Jose Manso, Arantzazu Alfranca, Ignacio Moreno-Pérez, et al.
European Urology|June 13, 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, David Olmos, Joaquin Mateo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2022
Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfoundKim N Chi, Alan Barnicle, Caroline Sibilla, et al.
Annals of Vascular Surgery|January 16, 2026
BIOSYNTHETIC PROSTHESIS OMNIFLOW® II IN CHRONIC-LIMB THREATENING ISCHEMIA. RESULTS OF THE MULTICENTER NATIONAL REGISTRY OMNI-FEMPOPAdriana Baturone, Francisco Javier Serrano, Lino Antonio Camblor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumorsTimothy A Yap, Li Yan, Amita Patnaik, et al.
The New England Journal of Medicine|April 29, 2020
Olaparib for Metastatic Castration-Resistant Prostate CancerJohann de Bono, Joaquin Mateo, Karim Fizazi, et al.
The Lancet. Oncology|October 13, 2012
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage studyDavid Olmos, Daniel Brewer, Jeremy Clark, et al.
Pageof 13